Alyeska Investment Group’s Xenon Pharmaceuticals XENE Stock Holding History

Alyeska Investment Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.1M	Sell	697,692 -601,777	-46%	-$33.4M	0.11%	227
2026 Q1	$75.6M	Buy	+1,299,469	New	+$59.9M	0.21%	139
2025 Q2	–	Sell	-367,233	Closed	-$12.3M	–	688
2025 Q1	$12.3M	Buy	367,233 +78,390	+27%	+$2.98M	0.05%	293
2024 Q4	$11.3M	Hold	288,843	–	–	0.04%	324
2024 Q3	$11.4M	Sell	288,843 -3,025	-1%	-$122K	0.06%	284
2024 Q2	$11.4M	Buy	291,868 +53,025	+22%	+$2.12M	0.07%	260
2024 Q1	$10.3M	Buy	+238,843	New	+$11M	0.06%	275
2018 Q2	–	Sell	-247,057	Closed	-$1.21M	–	537
2018 Q1	$1.21M	Sell	247,057 -2,227	-0.9%	-$8.23K	0.01%	381
2017 Q4	$704K	Sell	249,284 -200,000	-45%	-$544K	0.01%	397
2017 Q3	$1.32M	Buy	449,284 +8,024	+2%	+$24.8K	0.01%	403
2017 Q2	$1.39M	Buy	441,260 +1,366	+0.3%	+$5.34K	0.01%	376
2017 Q1	$1.76M	Buy	+439,894	New	+$3.46M	0.01%	405

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Alyeska Investment Group's XENE Position: Q2 2026 in Review

Alyeska Investment Group reduced its Xenon Pharmaceuticals (XENE) stake by 46% in Q2 2026, selling an estimated $33.4M and leaving 697,692 shares worth $42.1M. The position accounts for 0.11% of the portfolio, ranked #227.

Alyeska Investment Group first reported a position in XENE in Q1 2017 and has held it in 12 quarters since. The position peaked at $75.6M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Alyeska Investment Group held 697,692 shares of Xenon Pharmaceuticals worth $42.1M as of Q2 2026.
Alyeska Investment Group sold 601,777 Xenon Pharmaceuticals shares in Q2 2026, an estimated $33.4M.
Xenon Pharmaceuticals made up 0.11% of Alyeska Investment Group's portfolio in Q2 2026, its #227 holding.
Alyeska Investment Group first reported a position in Xenon Pharmaceuticals in Q1 2017 and has held it in 12 quarters since.
Alyeska Investment Group's Xenon Pharmaceuticals position peaked at $75.6M in Q1 2026.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.